BioLineRx (BLRX) Intangibles (2021 - 2025)

BioLineRx has reported Intangibles over the past 5 years, most recently at $16.4 million for Q4 2025.

  • Quarterly results put Intangibles at $16.4 million for Q4 2025, up 56.65% from a year ago — trailing twelve months through Dec 2025 was $16.4 million (up 56.65% YoY), and the annual figure for FY2025 was $16.4 million, up 56.65%.
  • Intangibles for Q4 2025 was $16.4 million at BioLineRx, up from $10.4 million in the prior quarter.
  • Over the last five years, Intangibles for BLRX hit a ceiling of $21.7 million in Q4 2021 and a floor of $801000.0 in Q4 2022.
  • Median Intangibles over the past 5 years was $10.4 million (2024), compared with a mean of $10.1 million.
  • Biggest five-year swings in Intangibles: plummeted 96.31% in 2022 and later soared 964.05% in 2024.
  • BioLineRx's Intangibles stood at $21.7 million in 2021, then plummeted by 96.31% to $801000.0 in 2022, then increased by 22.6% to $982000.0 in 2023, then soared by 964.05% to $10.4 million in 2024, then skyrocketed by 56.65% to $16.4 million in 2025.
  • The last three reported values for Intangibles were $16.4 million (Q4 2025), $10.4 million (Q4 2024), and $982000.0 (Q4 2023) per Business Quant data.